Europese Unie - Nederlands - EMA (European Medicines Agency)

dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - corticosteroïden en anti-infectives in combinatie - honden - behandeling van acute otitis externa.

Europese Unie - Nederlands - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otologicals - honden - behandeling van acute otitis externa en acute exacerbaties van recidiverende otitis externa, geassocieerd met bacteriën die vatbaar zijn voor orbifloxacine en schimmels die gevoelig zijn voor posaconazol, in het bijzonder malassezia pachydermatis.

Europese Unie - Nederlands - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunosuppressiva - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. de behandeling van ernstige, actieve en progressieve reumatoïde artritis bij volwassenen die niet eerder behandeld zijn met methotrexaat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita vermindert de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetert de fysieke functie, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita kan worden gegeven als monotherapie in geval van intolerantie voor methotrexaat of wanneer voortgezette behandeling met methotrexaat als ongepast (voor de werkzaamheid in monotherapie zie sectie 5. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita vermindert de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte (zie hoofdstuk 5. 1) en verbetert de fysieke functie. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 en 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ratiopharm gmbh graf-arco-strasse 3 89079 ulm (duitsland) - aciclovir 50 mg/g - crème - cetylalcohol ; dimeticon (e 900) ; macrogol-30-ether glycerolmonostearaat ; paraffine, vloeibaar (e905) ; paraffine, zacht (e 905) ; propyleenglycol (e 1520) ; water, gezuiverd, - aciclovir

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - deltamethrine - pour-on suspensie - deltamethrine 0,75 g/ml, - deltamethrin - runderen; schapen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

veterinary enterprises europe b.v. - deltamethrine - pour-on suspensie - deltamethrin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

alfasan nederland b.v. - clindamycinehydrochloride 0-water - zalf - clindamycinehydrochloride 0-water 10 mg/g, - clindamycin - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

virbac sa - deltamethrine - pour-on oplossing - deltamethrine 10 mg/ml, - deltamethrin - runderen; schapen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

chanelle pharmaceuticals manufacturing ltd - eprinomectine - pour-on oplossing - eprinomectine 5 mg/ml, - eprinomectin - melkkoeien; runderen

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bayer animal health gmbh - flumethrine; imidacloprid - halsband - flumethrine 0,56 g/stuk; imidacloprid 1,25 g/stuk, - flumethrin, combinations - honden